Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CMO Michael Shetzline sold 41,269 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ironwood Pharmaceuticals Price Performance

Shares of Ironwood Pharmaceuticals stock traded up $0.06 during trading on Wednesday, reaching $1.94. 3,432,794 shares of the company traded hands, compared to its average volume of 3,904,621. The firm has a market capitalization of $310.46 million, a PE ratio of -64.67 and a beta of 0.29. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.59 and a 1-year high of $15.70. The company has a 50 day moving average price of $3.63 and a 200-day moving average price of $4.18.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. KBC Group NV increased its stake in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $45,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $47,000. Xponance Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth about $50,000. Finally, Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth about $51,000.

Wall Street Analysts Forecast Growth

IRWD has been the subject of a number of recent research reports. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Craig Hallum reduced their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, JMP Securities reduced their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.